When actress Christina Applegate revealed that specialists determined she was misdiagnosed with Multiple Sclerosis (MS) after years of debilitating illness, it sparked shock. Yet within neurology, this reflects a documented reality: MS is frequently misdiagnosed, leaving many patients on unnecessary immunosuppressive therapies while their true conditions go unaddressed.
Because MS presents with fluctuating symptoms—such as fatigue, numbness, weakness, and visual changes—accurate diagnosis is challenging. Observational studies show that nearly one in five patients diagnosed with MS in community settings do not fulfill diagnostic criteria when evaluated at specialized academic centers. Understanding why errors occur, which conditions mimic MS, and how doctors verify diagnoses helps patients advocate effectively.
How Common Is Multiple Sclerosis Misdiagnosis?
To quantify diagnostic errors in demyelinating disease, academic centers have tracked referred patient cohorts. In a landmark multicenter study published in Multiple Sclerosis and Related Disorders, Dr. Marwa Kaisey and colleagues at Cedars-Sinai Medical Center and UCLA evaluated 241 patients referred with an established diagnosis of MS.
The investigators found that 18% of these patients did not fulfill diagnostic criteria. On average, misdiagnosed patients carried the wrong diagnosis for four years. Clinical consequences were substantial: 72% had been prescribed disease-modifying therapies (DMTs), and 48% received high-efficacy biologics carrying risks such as progressive multifocal leukoencephalopathy (PML).
These findings corroborated an earlier four-center cohort published in Neurology by Dr. Andrew J. Solomon. Among 110 confirmed misdiagnosed patients, one-third had carried the incorrect diagnosis for ten years or longer. Notably, a study limitation is that tertiary centers naturally encounter more complex or atypical cases than community practices.
Why Does MS Misdiagnosis Happen?
Unlike diabetes, Multiple Sclerosis has no single blood test that confirms its presence. Establishing a diagnosis relies on clinical synthesis, neuroimaging, and excluding plausible alternatives. Diagnostic errors typically stem from three recurring issues:
- Overreliance on Brain MRI Scans: MRI scans frequently reveal small bright spots on T2 and FLAIR sequences known as nonspecific white matter hyperintensities. These spots are common in migraine sufferers, individuals with hypertension, and during normal vascular aging. When clinicians misinterpret these benign vascular changes as active demyelinating MS plaques, misdiagnoses frequently follow.
- Misapplying Diagnostic Frameworks: The international McDonald Criteria were formulated specifically for individuals presenting with classic, objectively measurable clinically isolated syndromes. Applying these imaging criteria to patients experiencing subjective complaints like fatigue or widespread pain inflates false positives.
- Premature Diagnostic Closure: Once an initial MS diagnosis is recorded, providers often view symptoms through that lens, failing to reconsider alternatives even when treatments fail.
Conditions Frequently Mistaken for Multiple Sclerosis
Neurologists have identified several distinct conditions that simulate the symptoms and imaging findings of Multiple Sclerosis. The table below outlines how these common mimics differ across objective diagnostic parameters.
| Condition | Typical Symptoms | Characteristic MRI Findings | Key Confirmatory or Rule-Out Biomarker |
|---|---|---|---|
| Multiple Sclerosis (MS) | Relapsing focal deficits (vision loss, sensory ataxia, limb weakness) | Periventricular, juxtacortical, spinal lesions; Central Vein Sign positive | CSF oligoclonal bands positive in 85% to 95% of cases |
| Migraine with White Matter Spots | Throbbing headaches, visual auras, photophobia, sensory numbness | Small subcortical white matter spots; Central Vein Sign negative | Normal CSF; absent oligoclonal bands; no spinal cord lesions |
| Neuromyelitis Optica (NMOSD) | Bilateral optic neuritis, intractable hiccups/nausea, extensive myelitis | Longitudinally extensive spinal cord lesions (≥3 vertebral segments) | Serum AQP4-IgG positive in roughly 75% of cases |
| MOG Antibody Disease (MOGAD) | Recurrent optic neuritis, acute disseminated encephalomyelitis, myelitis | Optic nerve sheath swelling, conus lesions, deep gray lesions | Serum MOG-IgG autoantibodies positive |
| Vitamin B12 Deficiency | Symmetric peripheral neuropathy, loss of vibration sense, cognitive fog | Symmetric posterior/lateral spinal lesions; no brain plaques | Low serum B12, elevated methylmalonic acid (MMA) and homocysteine |
| Functional Neurological Disorder (FND) | Variable weakness or sensory loss, gait changes, chronic fatigue | Normal MRI or incidental age-related white matter spots | Positive distraction signs (e.g., Hoover’s sign); negative CSF bands |
Source: Kaisey et al. (2019), Solomon et al. (2016), and Thompson et al. (2018).
How Clinicians Accurately Confirm or Rule Out MS
Under the revised McDonald Criteria published in The Lancet Neurology, an accurate diagnosis requires proving two fundamental elements: Dissemination in Space (DIS) and Dissemination in Time (DIT). Dissemination in Space demands objective lesions affecting at least two of four core regions: periventricular, cortical/juxtacortical, infratentorial, and the spinal cord. Dissemination in Time requires demonstrating that lesions developed at distinct points, either through simultaneous gadolinium-enhancing and non-enhancing lesions on baseline MRI, or a new lesion on follow-up imaging.
When clinical presentation remains ambiguous, specialists employ specific diagnostic tools to safeguard against misdiagnosis:
- Lumbar Puncture and Oligoclonal Bands: Approximately 85% to 95% of individuals with confirmed MS exhibit unique immunoglobulin bands (oligoclonal bands) in their spinal fluid that are absent in blood serum. While absent bands do not entirely rule out MS, a negative spinal tap in a patient with atypical symptoms strongly warrants investigating other potential diagnoses.
- The Central Vein Sign (CVS): Research published in The Lancet Neurology evaluating 3-Tesla MRI protocols demonstrates that true MS lesions typically form directly around a central venule. In contrast, vascular or migraine spots develop along arteriole branches without a central vein. Assessing the Central Vein Sign drastically reduces false-positive interpretations.
- Targeted Autoantibody Serology: Blood tests for AQP4-IgG and MOG-IgG are now standard practice to differentiate MS from NMOSD and MOGAD. Distinguishing between these conditions is critical because several standard MS disease-modifying therapies can paradoxically trigger severe attacks in patients who actually have NMOSD.
- Spinal Cord Neuroimaging: Incidental white matter spots from migraine or aging occur almost exclusively in the cerebral hemispheres. If an MRI of the spinal cord demonstrates demyelinating lesions, the likelihood of a true demyelinating condition increases substantially. Conversely, a completely normal spinal cord MRI in a patient with extensive leg weakness or spasticity should raise immediate doubts regarding an MS diagnosis.
Navigating a Complex Neurological Diagnosis
Receiving an unexpected neurological diagnosis is destabilizing, but discovering years later that the diagnosis was incorrect brings its own emotional turmoil. If you or a loved one are navigating an MS diagnosis, clinical experts recommend proactive steps to ensure diagnostic precision:
- Seek Evaluation from an MS Specialist: Neurologists with fellowship training in neuroimmunology evaluate demyelinating conditions daily and are uniquely equipped to identify subtle mimics that general practitioners may overlook.
- Request an Imaging Re-Review: Having your MRI scans reviewed by an academic neuroradiologist can clarify whether white matter spots match demyelinating plaque morphology or represent non-inflammatory vascular changes.
- Heed Clinical Red Flags: Clinical signs that should prompt a second opinion include a complete lack of objective findings on a physical neurological exam, absent spinal cord lesions, normal cerebrospinal fluid, or failing to experience any stabilization after escalating through potent disease-modifying therapies.
Diagnostic accuracy is vital. As imaging protocols and biomarkers refine, clinicians can better ensure every patient receives targeted, appropriate care.
Sources and Further Reading
- Kaisey M, Solomon AJ, Luu M, Giesser BS, Sicotte NL. Incidence of multiple sclerosis misdiagnosis in referrals to two academic centers. Mult Scler Relat Disord. 2019;30:51-56. PubMed
- Solomon AJ, Bourdette DN, Cross AH, et al. The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study. Neurology. 2016;87(13):1393-1399. PubMed
- Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162-173. PubMed
- Sati P, Oh J, Constable RT, et al. The central vein sign and its clinical application for the diagnosis of multiple sclerosis: a consensus statement. Lancet Neurol. 2016;15(13):1338-1347. PubMed
- National Multiple Sclerosis Society. Diagnosing MS: Diagnostic Criteria and Testing Guidelines. National MS Society
Related Reading
- EBV Reactivation and Multiple Sclerosis: How Flares Begin
- Insomnia Therapy and Biological Aging: UCLA Trial Findings
Disclosure: This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.